Nothing Special   »   [go: up one dir, main page]

CN109394799B - Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof - Google Patents

Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof Download PDF

Info

Publication number
CN109394799B
CN109394799B CN201811624807.7A CN201811624807A CN109394799B CN 109394799 B CN109394799 B CN 109394799B CN 201811624807 A CN201811624807 A CN 201811624807A CN 109394799 B CN109394799 B CN 109394799B
Authority
CN
China
Prior art keywords
ganoderma lucidum
extract
lucidum extract
composition containing
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811624807.7A
Other languages
Chinese (zh)
Other versions
CN109394799A (en
Inventor
周亚杰
沈建
钱一帆
胡浪
陈晓红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongke Health Industry Group Jiangsu Pharmaceutical Co ltd
NANJING ZHONGKE PHARMACEUTICAL CO Ltd
Zhongke Health Industry Group Corp Ltd
Original Assignee
Zhongke Health Industry Group Jiangsu Pharmaceutical Co ltd
NANJING ZHONGKE PHARMACEUTICAL CO Ltd
Zhongke Health Industry Group Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongke Health Industry Group Jiangsu Pharmaceutical Co ltd, NANJING ZHONGKE PHARMACEUTICAL CO Ltd, Zhongke Health Industry Group Corp Ltd filed Critical Zhongke Health Industry Group Jiangsu Pharmaceutical Co ltd
Priority to CN201811624807.7A priority Critical patent/CN109394799B/en
Publication of CN109394799A publication Critical patent/CN109394799A/en
Application granted granted Critical
Publication of CN109394799B publication Critical patent/CN109394799B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/074Ganoderma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/066Clavicipitaceae
    • A61K36/068Cordyceps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/37Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a natural medicine composition containing ganoderma lucidum supercritical extract, a preparation method and application thereof, wherein the medicine composition comprises ganoderma lucidum extract and hirsutella hepiali Chen et Shen mycelium extract in a weight ratio of 2:1-1: 2. The invention has simple process and low production cost, and utilizes supercritical CO2The extracted ganoderma lucidum is combined with a hot water extraction method to extract hirsutella hepiali mycelia, and the extracts of the two are prepared into a natural medicinal composition according to a certain proportion, so that the natural medicinal composition has an obvious anti-tumor function.

Description

Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof
Technical Field
The invention belongs to the field of health-care food, and particularly relates to a natural pharmaceutical composition containing a ganoderma lucidum extract, and a preparation method and application thereof.
Background
Ganoderma lucidum is also known as Rue Cao and Xiancao, has mild nature and sweet taste, and is a precious Chinese herbal medicine which is always regarded as nourishing, body building, body resistance strengthening and body resistance strengthening by Chinese traditional medicine. The ganoderma lucidum is rich in components, including ganoderma lucidum polysaccharide, triterpene and steroid components, nucleoside, protein, trace elements and the like, wherein the ganoderma lucidum triterpene and the steroid components and the ganoderma lucidum polysaccharide are the main active substances and have been the focus of research in recent years. The modern medicine research shows that the ganoderma lucidum triterpenoids have the effects of resisting tumors, protecting the liver, reducing blood sugar, inhibiting angiotensin, resisting oxidation and the like; the ganoderan has effects of resisting tumor and aging, enhancing immunity, scavenging free radicals, and reducing blood sugar; the ganoderic acid has effects of enhancing disease resistance of human body, reducing cholesterol concentration in blood, and preventing prostate diseases. The components have the functions respectively and have the synergistic effect.
The existing market product is only a preparation of a single ganoderma lucidum extract, and a combined preparation which combines a hirsutella hepiali mycelium extract and a ganoderma lucidum extract and is used for better anti-tumor effect is not available.
Disclosure of Invention
The invention aims to solve the technical problem of the current state of the prior art and provides a natural medicinal composition containing a ganoderma lucidum extract and a hirsutella hepiali mycelium extract with an anti-tumor effect.
The purpose of the invention is realized by the following modes:
a natural pharmaceutical composition containing Ganoderma lucidum extract comprises Ganoderma lucidum extract and hirsutella hepiali Chen et Shen mycelium extract at a weight ratio of 2:1-1: 2.
Preferably, the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are mixed according to the proportion of 2:1-1: 1.
Further preferably, the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are mixed in a ratio of 2: 1.
The medicine composition and pharmaceutically acceptable auxiliary materials are prepared into an oral preparation. The oral preparation is preferably tablets, capsules, granules and pills.
The preparation method of the natural medicine composition containing the lucid ganoderma extract comprises the following steps:
(1) crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking lucid ganoderma fine powder obtained after crushing in an ethanol solution for 1-2 hours, and carrying out CO treatment on the soaked lucid ganoderma fine powder2Supercritical extraction, wherein the extraction conditions are as follows: the temperature of the extraction kettle is 38-42 ℃, the pressure of the extraction kettle is 30-35 MPa, and the extraction time is 3-4 h, so that the ganoderma lucidum extract is obtained;
(2) adding 20-30 times of water into hirsutella hepiali mycelia, boiling and extracting for 1-2h, soaking for more than 12h under heat preservation, boiling and extracting for 1-2h again, and concentrating to obtain a concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 2:1-1: 2.
The hirsutella hepialid Chen et Shen mycelia adopted by the invention are purchased from Hangzhou Zhongzhi kang mushroom biotechnology limited.
The natural medicine composition has obvious effect in preparing anti-tumor medicine.
Compared with the prior art, the invention has the beneficial effects that: the invention has simple process and low production cost, and utilizes supercritical CO2The ganoderma lucidum is extracted, hot water extraction is combined to extract hirsutella hepiali mycelia, and the extracts of the two are prepared into a natural medicinal composition according to a certain proportion, so that the natural medicinal composition has an obvious anti-tumor function.
The invention is further illustrated below by the efficacy of the inhibition of animal transplantable tumors:
1 test Material
1.1 test drugs: the invention (product of example 1, abbreviated as No. 1), (product of example 2, abbreviated as No. 2), (product of example 3, abbreviated as No. 3), Ganoderma lucidum extract group (total Ganoderma lucidum extract, abbreviated as No. 4), and hirsutella hepiali Chen et Shen mycelium group (total hirsutella hepiali Chen et Shen mycelium extract, abbreviated as No. 5).
1.2 animals: ICR mouse, 18-22g, male and female halves, provided by animal laboratories of Chinese university of pharmacy, wherein the feed is pellet feed, and the feeding conditions are as follows: air-conditioned room, temperature 18-24 deg.C, relative humidity 70%.
1.3 Positive drugs: cyclophosphamide (CTX), shengdi pharmaceutical ltd, Jiangsu. Specification: 0.2 g/bottle.
2 main contents of experiment
2.11, 2, 3, 4 and 5 tail vein injections have the inhibiting effect on Heps of mouse transplantation tumor.
2.21, 2, 3, 4 and 5 tail vein injection on the mouse transplantation tumor S180.
3 Experimental methods and procedures
3.11, 2, 3, 4 and 5 tail vein injections have the inhibiting effect on Heps of mouse transplantation tumor.
3.1.1 routes of administration: tail vein injections No. 1, No. 2, No. 3, No. 4, No. 5 (iv)
3.1.2 dosing cycle: heps solid type was inoculated according to the transplantation tumor study, administered 24 hours after inoculation, iv administered once every other day for 4 times total, and dissected mice were sacrificed on day 2 after drug withdrawal.
3.1.3 dose settings 7 groups, respectively:
blank control group (physiological saline)
No. 1: 3mg/kg
No. 2: 3mg/kg
No. 3: 3mg/kg
No. 4: 3mg/kg
No. 5: 3mg/kg
CTX:30mg/kg
3.1.4 dosing volumes: 0.4ml/20g
3.1.5 methods of experiment: 70 mice with the specification are inoculated with Heps solid types according to a transplantation tumor research method, the mice are weighed 24 hours after inoculation and are randomly divided into 7 groups, 10 mice in each group are half male and female, and a blank control group and a CTX group are respectively a negative control group and a positive control group. Administration 24 hours after inoculation, iv administration, once every other day, 4 total administrations, mice weighed on day 2 after drug withdrawal, tumor bearing mice sacrificed and tumor masses were isolated, weighed and the data statistically processed (t-test).
3.1.6 results of the experiment
The results are shown in Table 1, and the results show that the group iv of No. 1 and No. 2 can obviously inhibit the tumor growth effect of Heps (P is less than 0.05, P is less than 0.01) compared with the blank control group, and simultaneously has the effect of reducing the body weight of experimental mice, but has little influence compared with the positive drug CTX group, and the effect is better than that of the group No. 3, No. 4 and No. 5.
Table 11, 2, 3, 4, 5 iv inhibition of Heps in mice transplantable tumors (X ± SD) (n ═ 10)
Figure BDA0001927745980000031
Figure BDA0001927745980000041
Note: p < 0.05P < 0.01 in comparison with the blank control group
Inhibition of mouse graft tumor S180 by tail vein injection of No. 3.21, No. 2, No. 3, No. 4 and No. 5
3.2.1 routes of administration: tail vein injection No. 1, No. 2, No. 3, No. 4, No. 5 (iv)
3.2.2 dosing cycle: s180 solid type was inoculated according to the transplanted tumor study, administered 24 hours after inoculation, iv administered once every other day for 4 times total, and dissected mice were sacrificed on day 2 after drug withdrawal.
3.2.3 dose settings: totally set 7 groups, respectively:
blank control group (physiological saline)
No. 1: 3mg/kg
No. 2: 3mg/kg
No. 3: 3mg/kg
No. 4: 3mg/kg
No. 5: 3mg/kg
CTX:30mg/kg
3.2.4 dosing volumes: 0.4ml/20g
3.2.5 Experimental methods: 70 mice with the specification are inoculated with an S180 solid type according to a transplantation tumor research method, the weight of the mice is weighed 24 hours after inoculation, the mice are randomly divided into 7 groups, each group comprises 10 mice, the male and female groups are half, and a blank control group and a CTX group are respectively a negative control group and a positive control group. Administration 24 hours after inoculation, iv administration, once every other day, 4 total administrations, mice weighed on day 2 after drug withdrawal, tumor bearing mice sacrificed and tumor masses were isolated, weighed and the data statistically processed (t-test).
The results of 3.2.6 are shown in Table 4, and the results show that the group IV administration of the group 1 can obviously inhibit the tumor growth effect of S180 (P is less than 0.01) compared with the blank control group, and simultaneously has the effect of reducing the body weight of the experimental mouse, but has little influence compared with the positive drug CTX group, and the effect is obviously superior to the group 2-5.
Table 41, 2, 3 iv inhibition of mouse graft tumor S180 (X ± SD) (n ═ 10)
Figure BDA0001927745980000042
Figure BDA0001927745980000051
Note: p < 0.05P < 0.01 in comparison with the blank control group
Therefore, the invention combines the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract for use, the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are mutually coordinated and interacted, and the advantages of the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are combined, thereby obviously improving the utilization rate of the composition and enhancing the effect of inhibiting the animal transplantation tumor.
Detailed Description
The invention is further illustrated by the following specific examples:
example 1
(1) Crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in a 95% ethanol solution for 1 hour, and carrying out CO treatment on the soaked lucid ganoderma powder2Supercritical extraction, wherein the extraction conditions are as follows: the temperature of the extraction kettle is 40 ℃, the extraction time is 3 hours, and the extraction pressure is 30MPa, so that the ganoderma lucidum extract is obtained;
(2) adding 30 times volume of water into hirsutella hepiali mycelia, boiling and extracting for 2h, soaking for 12h, boiling and extracting for 2h, and concentrating to obtain concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali Chen et Shen mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 2: 1.
Example 2
(1) Crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in a 95% ethanol solution for 2 hours, and carrying out CO treatment on the soaked lucid ganoderma fine powder2Supercritical extraction, extractionTaking conditions as follows: the temperature of the extraction kettle is 38 ℃, the pressure of the extraction kettle is 32MPa, and the extraction time is 4 hours, so that the ganoderma lucidum extract is obtained;
(2) adding 20 times of water into hirsutella hepiali mycelia, boiling and extracting for 1h, soaking for 12h, boiling and extracting for 2h, and concentrating to obtain concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali Chen et Shen mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 1: 1.
Example 3
(1) Crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in a 95% ethanol solution for 2 hours, and carrying out CO treatment on the soaked lucid ganoderma powder2Supercritical extraction, wherein the extraction conditions are as follows: extracting at 42 deg.C under 35MPa for 4 hr to obtain Ganoderma extract;
(2) adding 25 times of water into hirsutella hepiali mycelia, boiling and extracting for 2h, soaking for 12h, boiling and extracting for 2h, and concentrating to obtain concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali Chen et Shen mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 1: 2.

Claims (4)

1. A natural medicine composition containing ganoderma lucidum extract is characterized in that the medicine composition comprises the following components in percentage by weight
2:1, the preparation method comprises the following steps:
(1) crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in an ethanol solution for 1-2 hours, and carrying out CO treatment on soaked lucid ganoderma fine powder2Supercritical extraction, wherein the extraction conditions are as follows: the temperature of the extraction kettle is 38-42 ℃, the pressure of the extraction kettle is 30-35 MPa, and the extraction time is 3-4 h, so that the ganoderma lucidum extract is obtained;
(2) adding 20-30 times of water into hirsutella hepiali mycelia, boiling and extracting for 1-2h, soaking for more than 12h under heat preservation, boiling and extracting for 1-2h again, and concentrating to obtain a concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 2: 1.
2. The natural pharmaceutical composition containing ganoderma lucidum extract as claimed in claim 1, wherein the pharmaceutical composition is prepared into an oral preparation together with pharmaceutically acceptable excipients.
3. The natural pharmaceutical composition containing ganoderma lucidum extract according to claim 1, wherein the oral preparation is tablet, capsule, granule or pill.
4. Use of the natural pharmaceutical composition containing ganoderma lucidum extract according to claims 1-3 for the preparation of an anti-tumor medicament.
CN201811624807.7A 2018-12-28 2018-12-28 Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof Active CN109394799B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811624807.7A CN109394799B (en) 2018-12-28 2018-12-28 Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811624807.7A CN109394799B (en) 2018-12-28 2018-12-28 Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN109394799A CN109394799A (en) 2019-03-01
CN109394799B true CN109394799B (en) 2021-05-28

Family

ID=65462353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811624807.7A Active CN109394799B (en) 2018-12-28 2018-12-28 Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN109394799B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237107A (en) * 2019-05-31 2019-09-17 嘉兴市爵拓科技有限公司 Preparation method, its composition and its application of a kind of mountain Soviet Union extract

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102379905B (en) * 2011-06-22 2013-07-24 南京中科药业有限公司 Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance
CN108392500A (en) * 2018-03-30 2018-08-14 上海市农业科学院 A method of preparing ganodenic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102379905B (en) * 2011-06-22 2013-07-24 南京中科药业有限公司 Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance
CN108392500A (en) * 2018-03-30 2018-08-14 上海市农业科学院 A method of preparing ganodenic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蝙蝠蛾被毛孢菌丝体通过激活TLR2、TLR4和Dectin-1诱导Th1型免疫反应;陈志蓉等;《中国免疫学杂志》;20091020(第10期);895-902 *

Also Published As

Publication number Publication date
CN109394799A (en) 2019-03-01

Similar Documents

Publication Publication Date Title
JP6305457B2 (en) Application of herbal medicine composition to the preparation of health foods and medicines for the relief and prevention treatment of physical fatigue
CN103768534B (en) A kind of Chinese medicine composition with antitumor activity
CN101703530A (en) Mixed fungus ultrafine powder and preparation method thereof
CN111035649B (en) NMN + GLP compound nutritional supplement and preparation method and application thereof
CN101724667A (en) Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application
CN104306410A (en) Triterpene-enriched anti-tumor composition and preparation method thereof
CN1762236B (en) Health-caring product capable of increasing human immunity and its preparation method
CN105395919A (en) Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition
CN101380346B (en) Traditional Chinese composition for treating tumor and production method thereof
JP6389958B2 (en) Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins
CN101467673A (en) Compound ginseng health product and preparation method thereof
CN107929337A (en) A kind of preparation method and application of Panax stipuleanatus Tsai et Feng anti-inflammatory active component
CN109394799B (en) Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof
CN1903227A (en) Water soluble active component of fermented cordyceps and its application
CN106581166A (en) Anti-fatigue food, health product or pharmaceutical composition
CN106728208A (en) A kind of ginseng and lucid ganoderma polysaccharide triterpene preparation and preparation method thereof
Arora Cordyceps sinensis (berk.) sacc.-an entomophagous medicinal fungus-a review
CN104857180B (en) Composition for resisting fatigue and improving immunity and preparation method and application thereof
CN112076281A (en) Ganoderma applanatum composition for enhancing immunity and preparation method thereof
CN108578578B (en) Pharmaceutical composition with blood fat reducing effect and preparation method thereof
CN110663948A (en) Health product with immunity enhancing effect and preparation method thereof
CN112870282A (en) Areca catechu extract for improving gastric motility and preparation process and application thereof
CN104510857B (en) A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof
CN107927745B (en) A Chinese medicinal health food composition, and its preparation method and preparation
CN104147070B (en) A kind of pharmaceutical composition and its preparation process of Prophylactic chemotherapy oral inflammation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant